Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
04/2005
04/19/2005US6881733 Serotonergic benzofurans
04/19/2005US6881727 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
04/19/2005CA2299967C Taxoid compound and method for producing the same
04/19/2005CA2260989C Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof
04/14/2005WO2005033930A2 Process for upgrading naphtha
04/14/2005WO2005033342A1 Detection of immobilized nucleic acid
04/14/2005WO2005033104A1 Use of a compound of formula (i) as an inhibitor of aromatase for therapeutic purposes and compounds of formula (1) thereas
04/14/2005WO2005033103A1 Quinoline compounds and their uses
04/14/2005WO2005033102A2 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
04/14/2005WO2005033096A1 Quinoline derivatives and quinazoline derivatives, medicaments containing said compounds, use thereof, and method for the production thereof
04/14/2005WO2005033095A1 Fungicidal 4-(2-aminopyridin-4-yl)-n-phenyl-1,3,5-triazin-2-amine derivatives
04/14/2005WO2005032550A2 Peptide deformylase inhibitors
04/14/2005WO2005032548A1 Substituted benzazoles and use thereof as inhibitors of raf kinase
04/14/2005WO2005032493A2 Amide compounds as ion channel ligands and uses thereof
04/14/2005WO2005032464A2 Phenyl pyrrolidine ether tachykinin receptor antagonists
04/14/2005WO2005017126A3 Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
04/14/2005WO2005016883A3 Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
04/14/2005WO2005012241A3 p-38 KINASE INHIBITORS
04/14/2005WO2005007111A3 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
04/14/2005WO2005002503A3 Asymmetric benzimidazoles and related compounds as potassium channel modulators
04/14/2005WO2004092124A3 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
04/14/2005US20050080272 Halogenated nitrobutadienes for controlling animal pests
04/14/2005US20050080265 Sleep disorders; side effect reduction
04/14/2005US20050080258 Kinase inhibitors; autoimmune disease; antiinflammatory agents
04/14/2005US20050080117 Substituted benzoxazoles as estrogenic agents
04/14/2005US20050080116 Compounds useful as motilin agonists and method
04/14/2005US20050080111 Antagonists of liver X receptors; control of cholesterol, triglyceride, or bile acid levels; 6-(1-Benzyl-1H-pyrazol-4-yl)-1-(2,4-difluoro-benzyl)-2-oxo-4-trifluoromethyl-1,2-dihydro-pyridine-3-carbonitrile
04/14/2005US20050080110 Treating Type 2 diabetes and/or obesity; compounds are indoles substituted at position 3 with a (3-(2-(heterocycle-substituted)phenoxy)-2-hydroxypropylamino)alkyl group
04/14/2005US20050080106 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes
04/14/2005US20050080101 N-[4-(pyrazolyl)-pyrimidin-2-yl]-N-phenyl-amine derivatives
04/14/2005US20050080091 Capped pyrazinoylguanidine sodium channel blockers
04/14/2005US20050080087 For treatment of metabolic disorders, eating disorders, appetitive disorders, psychiatric disorders, memory impairment, Parkinson's disease, Alzheimer's disease, substance abuse, leukocyte activation-associated disorders, and inflammatory diseases
04/14/2005US20050080081 Substituted oxazolidinones and their use in the field of blood coagulation
04/14/2005US20050080079 N-[4-[[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]thio]phenyl]ethanesulfonamide for example; potassium channel modulators for treating erectile dysfunction and irritable bowel syndrome
04/14/2005US20050080078 Such as [1-(4-chloro-phenyl)-cyclobutyl]-(3-hydroxymethyl piperidin-1-yl)-methadone for treating cocaine and/or methamphetamine addiction
04/14/2005US20050080003 Compounds with anti-inflammatory activity
04/14/2005US20050079979 Substituted benzoylisoxazoles and the use thereof as herbicides
04/14/2005US20050079176 Treating stress response with chemokine receptor ccr5 modulators
04/14/2005CA2541299A1 Amide compounds as ion channel ligands and uses thereof
04/14/2005CA2540517A1 Process for upgrading naphtha
04/14/2005CA2540508A1 Detection of immobilized nucleic acid
04/14/2005CA2540502A1 Use of a compound of formula (i) as an inhibitor of aromatase for therapeutic purposes and compounds of formula (1) thereas
04/14/2005CA2540061A1 Phenyl pyrrolidine ether tachykinin receptor antagonists
04/14/2005CA2539748A1 Substituted benzazoles and use thereof as inhibitors of raf kinase
04/13/2005EP1521748A1 Novel anthracene derivatives and the use thereof as a medicament
04/13/2005EP1521747A2 Receptor-type kinase modulators and methods of use
04/13/2005EP1521746A1 Quinazolinone modulators of nuclear receptors
04/13/2005EP1521733A1 Modulators of the glucocorticoid receptor
04/13/2005EP1289955B1 Piperidines for use as orexin receptor antagonists
04/13/2005EP1242416B1 Substituted isoxazolines and their use as antibacterial agents
04/13/2005EP0880507B1 Quinazoline derivatives as antitumor agents
04/13/2005CN1606554A Beta-lactamyl vasopressin v1aantagonists
04/13/2005CN1606553A Oxytocin agonistenoxytocin agonisten
04/13/2005CN1606551A Substituted 2-phenyl benzofurans as estrogenic agents
04/13/2005CN1606545A Pyrrolidine and piperidine derivates as nk1 antagonists
04/13/2005CN1606544A Bicyclic compound
04/13/2005CN1606439A Cis-imidazolines
04/13/2005CN1196696C New thiochromane derivatives and use as thrombin inhibitors
04/13/2005CN1196687C Inhibitors of IMPDH enzyme
04/13/2005CN1196685C Pyrimidine derivatives
04/13/2005CN1196485C Compositions for use against parasitic protozoa
04/12/2005US6878743 Controlling apoptosis; central nervous system disorders
04/12/2005US6878739 Composition for treating or preventing glomerulopathy
04/12/2005US6878734 Gastrin and cholecystokinin receptor ligands(II)
04/12/2005US6878727 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
04/12/2005US6878720 VEGF receptor tyrosine kinase inhibitors
04/12/2005US6878718 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
04/12/2005US6878714 Prophylaxis and treatment of angiogenesis mediated diseases such as cancer
04/12/2005US6878713 Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
04/12/2005CA2174107C Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
04/12/2005CA2128380C 4-aryloxy- and 4-arylthiopiperidine derivatives
04/12/2005CA2122571C Adhesion receptor antagonists
04/07/2005WO2005030765A1 Quinazoline derivatives as antiproliferative agents
04/07/2005WO2005030764A1 Process for the preparation of chiral propionic acid derivatives
04/07/2005WO2005030763A1 Benzisoxazoles
04/07/2005WO2005030762A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
04/07/2005WO2005030761A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
04/07/2005WO2005030758A1 Pyrimidine and pyridine derivatives useful as hmg-coa reductase inhibitors and method of preparation thereof
04/07/2005WO2005030757A1 Quinazoline derivatives
04/07/2005WO2005030755A1 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
04/07/2005WO2005030754A1 Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity
04/07/2005WO2005030753A2 Therapeutic agents useful for treating pain
04/07/2005WO2005030739A1 Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof
04/07/2005WO2005030733A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof
04/07/2005WO2005030712A2 Thrombin receptor antagonists
04/07/2005WO2005030206A1 Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
04/07/2005WO2005030204A1 Substituted oxadiazolidinediones as pai-1 inhibitors
04/07/2005WO2005030203A1 Substituted oxadiazolidinediones als pai-1 inhibitors
04/07/2005WO2005030140A2 C-met modulators and methods of use
04/07/2005WO2005030131A2 Bis-quinazoline compounds for the treatment of bacterial infections
04/07/2005WO2005016918A3 Heterocyclic n-aryl carboxamides as cytokine inhibitors
04/07/2005WO2005012256A8 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
04/07/2005WO2005009975A3 Benzimidazole derivatives as mek inhibitors
04/07/2005WO2005007647A9 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
04/07/2005WO2004112719A3 Chemical compounds
04/07/2005WO2004112709A3 Inhibitors of cathepsin s
04/07/2005WO2004014871A8 Vanilloid receptor ligands and their use in treatments
04/07/2005US20050075506 Process for preparing florfenicol
04/07/2005US20050075394 Phenethanolamine derivatives for treatment of respiratory diseases
04/07/2005US20050075390 HIV protease inhibitors
1 ... 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 ... 647